Rocket Pharma swings to Q2 FY26 net income of $123.2 million; R&D expenses fall 30.92% to $29.5 million
Reuters2026/08/10 20:01- Rocket Pharmaceuticals turned profitable in Q2 2026, posting net income of USD 123.2 million, versus a net loss of USD 68.9 million a year earlier.
- R&D expense fell 30.92% to USD 29.5 million, driven by lower manufacturing and development costs plus reduced stock-based compensation and headcount.
- G&A expense dropped 30.4% to USD 17.4 million, on lower commercial preparation spending, stock-based compensation, and legal costs.
- Other income climbed to USD 178.8 million on a net USD 178.2 million gain from selling a Priority Review Voucher, lifting cash to USD 283.7 million.
- All three initial RP-A501 Danon patients cleared the safety observation period with no TMA or capillary leak; cash runway forecast into Q2 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stocks closed with BNC surging 50.43%
Spending 590 millions dollars to acquire Stride Bank’s license, Chime (CHYM.US) is crowned as a licensed bank, transitioning from a fintech “challenger” to a “licensed bank.”
Chime Financial Inc. (CHYM.US) has reached an agreement to acquire its long-term partner Stride Bank for $590 million in cash, marking a key step in operational integration for the fintech company.
The South Korean stock market is brewing bottom-fishing opportunities: foreign capital sell-off slows, Korean won strengthens, and KOSPI 200 valuation drops to the first decile in ten years.
After a deleveraging phase and concentrated foreign selling, the South Korean stock market is experiencing a dual turning point in both valuation and technical indicators. On September 8, the Korean stock index broke above its short-term downtrend line and closed above the 50-day moving average for the first time. The forward P/E ratio of KOSPI 200 is only 6.2x, ranking in the first percentile of the past ten years. Analysts believe this extreme discount provides strong downside protection.
Grab Chief Org Capability Officer Ong Chin Yin disposes of $130,412.2 in common shares
Crypto prices
More
